UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Enhancer dysfunction in leukemia

Blood, 2018-04, Vol.131 (16), p.1795-1804

2018

Volltextzugriff (PDF)

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

Blood, 2009-10, Vol.114 (14), p.2984-2992

2009

Volltextzugriff (PDF)

CD13/APN is activated by angiogenic signals and is essential for capillary tube formation

Blood, 2001-02, Vol.97 (3), p.652-659

2001

Volltextzugriff (PDF)

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms

Blood, 2014-03, Vol.123 (13), p.2075-2083

2014

Volltextzugriff (PDF)

PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Anti-Leukemic Activity in Preclinical Primary Models of Human B-ALL, T-ALL, and CLL

Blood, 2022-11, Vol.140 (Supplement 1), p.505-506

2022

Volltextzugriff (PDF)

The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis

Blood, 2003-03, Vol.101 (5), p.1818-1826

2003

Volltextzugriff (PDF)

PRMT5 Inhibition Alters Mitochondrial Dynamics in Mantle Cell Lymphoma Creating Vulnerability to BH3 Mimetic Compounds

Blood, 2022-11, Vol.140 (Supplement 1), p.3118-3119

2022

Volltextzugriff (PDF)

A Phase 1 Dose Escalation Study of Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Patients with Myeloid Malignancies

Blood, 2021-11, Vol.138 (Supplement 1), p.2609-2609

2021

Volltextzugriff (PDF)

PRMT5 Inhibition Potentiates Anti-Tumor Immune Targeting of EBV-Driven B Cell Lymphoproliferative Disease

Blood, 2022-11, Vol.140 (Supplement 1), p.3116-3117

2022

Volltextzugriff (PDF)

Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis

Blood, 2014-10, Vol.124 (14), p.2280-2284

2014

Volltextzugriff (PDF)

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias

Blood, 2015-11, Vol.126 (22), p.2479-2483

2015

Volltextzugriff (PDF)

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Blood, 2019-11, Vol.134 (Supplement_1), p.473-473

2019

Volltextzugriff (PDF)

Mathematical Optimization of JAK Inhibitor Dose and Scheduling for MPN Patients

Blood, 2014-12, Vol.124 (21), p.911-911

2014

Volltextzugriff (PDF)

Proteomic Analysis of Reprograming of Mesenchymal Stem/Stromal Cells (MSC) Following Interferon Gamma Identifies Pathways That Are Upregulated in Suppression

Blood, 2015-12, Vol.126 (23), p.384-384

2015

Volltextzugriff (PDF)

Combination Therapy Using JAK2 and HSP90 Inhibitors Increased Efficacy in Myelofibrosis in Vivo

Blood, 2012-11, Vol.120 (21), p.805-805

2012

Volltextzugriff (PDF)

Improved Efficacy Of Combination Of JAK2 and Hedgehog Inhibitors In Myelofibrosis

Blood, 2013-11, Vol.122 (21), p.666-666

2013

Volltextzugriff (PDF)

Robust Factor IX Expression Following ZFN-Mediated Genome Editing in An Adult Mouse Model of Hemophilia B

Blood, 2011-11, Vol.118 (21), p.668-668

2011

Volltextzugriff (PDF)

AC220, a FLT3 Inhibitor, Increases Survival in Two Genotypically Distinct FLT3-ITD Models of Acute Myeloid Leukemia and Provides Sustained Protection Following Chronic Administration

Blood, 2009-11, Vol.114 (22), p.2053-2053

2009

Volltextzugriff (PDF)

AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Cell Culture and in Mouse Tumor Xenografts

Blood, 2009-11, Vol.114 (22), p.2052-2052

2009

Volltextzugriff (PDF)

Heterodimeric JAK-STAT Activation As a Mechanism of Persistence to JAK2 Inhibitor Therapy

Blood, 2011-11, Vol.118 (21), p.122-122

2011

Volltextzugriff (PDF)

Phenotypic Correction of a Mouse Model of Hemophilia B by In Vivo Genetic Correction of the F9 Gene

Blood, 2010-11, Vol.116 (21), p.LBA-5-LBA-5

2010

Volltextzugriff (PDF)

AC220 Is a Uniquely Potent and Selective Second-Generation FLT3 Inhibitor

Blood, 2008-11, Vol.112 (11), p.859-859

2008

Volltextzugriff (PDF)

Efficacy of the Novel Non-Quinone Based HSP-90 Inhibitor PU-H71 in JAK2V617F and MPLW515L-Induced Murine Models of Myeloproliferative Neoplasms

Blood, 2009-11, Vol.114 (22), p.3898-3898

2009

Volltextzugriff (PDF)

Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Assessment of Consistency and Robustness of Treatment Benefit for Patients in First Complete Remission

Blood, 2008-11, Vol.112 (11), p.1948-1948

2008

Volltextzugriff (PDF)

Impact on Quality of Life of Postconsolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in Acute Myelogenous Leukemia

Blood, 2007-11, Vol.110 (11), p.4381-4381

2007

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieBlood

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Menü

Weitere Dienste

Einstellungen

Enhancer dysfunction in leukemia

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

CD13/APN is activated by angiogenic signals and is essential for capillary tube formation

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms

PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Anti-Leukemic Activity in Preclinical Primary Models of Human B-ALL, T-ALL, and CLL

The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis

PRMT5 Inhibition Alters Mitochondrial Dynamics in Mantle Cell Lymphoma Creating Vulnerability to BH3 Mimetic Compounds

A Phase 1 Dose Escalation Study of Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Patients with Myeloid Malignancies

PRMT5 Inhibition Potentiates Anti-Tumor Immune Targeting of EBV-Driven B Cell Lymphoproliferative Disease

Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Mathematical Optimization of JAK Inhibitor Dose and Scheduling for MPN Patients

Proteomic Analysis of Reprograming of Mesenchymal Stem/Stromal Cells (MSC) Following Interferon Gamma Identifies Pathways That Are Upregulated in Suppression

Combination Therapy Using JAK2 and HSP90 Inhibitors Increased Efficacy in Myelofibrosis in Vivo

Improved Efficacy Of Combination Of JAK2 and Hedgehog Inhibitors In Myelofibrosis

Robust Factor IX Expression Following ZFN-Mediated Genome Editing in An Adult Mouse Model of Hemophilia B

AC220, a FLT3 Inhibitor, Increases Survival in Two Genotypically Distinct FLT3-ITD Models of Acute Myeloid Leukemia and Provides Sustained Protection Following Chronic Administration

AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Cell Culture and in Mouse Tumor Xenografts

Heterodimeric JAK-STAT Activation As a Mechanism of Persistence to JAK2 Inhibitor Therapy

Phenotypic Correction of a Mouse Model of Hemophilia B by In Vivo Genetic Correction of the F9 Gene

AC220 Is a Uniquely Potent and Selective Second-Generation FLT3 Inhibitor

Efficacy of the Novel Non-Quinone Based HSP-90 Inhibitor PU-H71 in JAK2V617F and MPLW515L-Induced Murine Models of Myeloproliferative Neoplasms

Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Assessment of Consistency and Robustness of Treatment Benefit for Patients in First Complete Remission

Impact on Quality of Life of Postconsolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in Acute Myelogenous Leukemia

Aktive Filter

Suchergebnisse filtern